Advertisement

Rucaparib vs Chemotherapy for Relapsed BRCA-Mutated Ovarian Cancer
Posted: 03/18/2025 | By: Sarah Campen, PharmD

Most patients with advanced high-grade serous ovarian cancer respond to initial treatment, but the majority relapse. Final survival data and other post-progression outcomes from the ARIEL4 trial of rucaparib vs chemotherapy in patients with relapsed BRCA-mutated ovarian cancer were recently published in The Lancet.

Question 1 of 5

Which of the following patients would have been potentially eligible for inclusion in the ARIEL4 trial?

Choose 1

A
A 65-year-old woman with BRCA1-mutated ovarian cancer previously treated with only one platinum-based chemotherapy regimen followed by olaparib monotherapy
B
A 26-year-old woman with BRCA2-mutated platinum-resistant ovarian cancer after failing two chemotherapy regimens
C
A 57-year-old woman with newly diagnosed BRCA2-mutated ovarian cancer
D
A 74-year-old woman with TP53-mutated ovarian cancer previously treated with two regimens of chemotherapy

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage